Haemoglobin and Anaemia in the Smart Study

Volberding P.A. , Levine A.M. , Dieterich D. , Mildvan D. , Mitsuyasu R. , Saag M. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis 2004; 38: 1454–1463.

Sullivan P.S. , Hanson D.L. , Chu S.Y. , Jones J.L. , Ward J.W. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91: 301–308.

Curkendall S.M. , Richardson J.T. , Emons M.F. , Fisher A.E. , Everhard F. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2007; 8: 483–490.

Zhou J. , Kumarasamy N. Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med 2005; 6: 216–223.

Anastos K. , Shi Q. , French A.L. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35: 383–392.

Harris R.J. , Sterne J.A. , Abgrall S. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008; 13: 959–967.

Justice A.C. , McGinnis K.A. , Skanderson M. Towards a combined prognostic index for survival in HIV infection: the role of ‘non-HIV’ biomarkers. HIV Med 2010; 11: 143–151.

Mocroft A. , Kirk O. , Barton S.E. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999; 13: 943–950.

Westenbrink B.D. , de Boer R.A. , Voors A.A. , van Gilst W.H. , van Veldhuisen D.J. Anemia in chronic heart failure: etiology and treatment options. Curr Opin Cardiol 2008; 23: 141–147.

Blohmer J.U. , Dunst J. , Harrison L. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 2005; 68 Suppl 1: 12–21.

Mitchell J.E. Emerging role of anemia in heart failure. Am J Cardiol 2007; 99 Suppl 2: S15–S20.

Iseki K. , Kohagura K. Anemia as a risk factor for chronic kidney disease. Kidney Int Suppl 2007; 72: S4–S9.

Mocroft A. , Reiss P. , Gasiorowski J. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55: 262–270.

Moh R. , Danel C. , Sorho S. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 2005; 10: 615–624.

Ssali F. , Stohr W. , Munderi P. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 2006; 11: 741–749.

Hughes W.T. , LaFon S.W. , Scott J.D. , Masur H. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis 1995; 171: 1295–1301.

Fangman J.J. , Scadden D.T. Anemia in HIV-infected adults: epidemiology, pathogenesis, and clinical management. Curr Hematol Rep 2005; 4: 95–102.

McGinniss M.H. , Macher A.M. , Rook A.H. , Alter H.J. Red cell autoantibodies in patients with acquired immune deficiency syndrome. Transfusion 1986; 26: 405–409.

Rule S. , Reed C. , Costello C. Fatal haemophagocytic syndromes in HIV-antibody positive patient. Br J Haematol 1991; 79: 127.

Sasadeusz J. , Buchanan M. , Speed B. Reactive haemophagocytic syndrome in human immunodeficiency virus infection. J Infect 1990; 20: 65–68.

Moore R.D. , Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 54–57.

Berhane K. , Karim R. , Cohen M.H. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 37: 1245–1252.

The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4⁺ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283–2296.

SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149: 289–299.

Berliner N. , Duffy T. , Abelson H.T. Approach to the adult and child with anemia. In Hoffman R.H. , Beric E.J. , Shattil S.J. ., (Editors). Hematology: basic principles and practice. 2nd Ed. Philadelphia: Churchill Livingstone 1995; pp. 468–483.

Neuhaus J. , Angus B. , Kowalska J.D. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24: 697–706.

Zakai N.A. , Katz R. , Hirsch C. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 2005; 165: 2214–2220.

Ma J.Z. , Ebben J. , Xia H. , Collins A.J. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610–619.

Nissenson A.R. , Goodnough L.T. , Dubois R.W. Anemia: not just an innocent bystander? Arch Intern Med 2003; 163: 1400–1404.

Sarnak M.J. , Tighiouart H. , Manjunath G. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002; 40: 27–33.

Lederman M.M. , Kalish L.A. , Asmuth D. , Fiebig E. , Mileno M. , Busch M.P. 'Modeling’ relationships among HIV-1 replication, immune activation and CD4⁺ T-cell losses using adjusted correlative analyses. AIDS 2000; 14: 951–958.

Sodora D.L. , Silvestri G. Immune activation and AIDS pathogenesis. AIDS 2008; 22: 439–446.

Rodger A.J. , Fox Z. , Lundgren J.D. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200: 973–983.

Kuller L.H. , Tracy R. , Belloso W. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.

Mocroft A. , Ledergerber B. , Zilmer K. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS 2007; 21: 1867–1875.

Subbaraman R. , Devaleenal B. , Selvamuthu P. Factors associated with anaemia in HIV-infected individuals in southern India. Int J STD AIDS 2009; 20: 489–492.

Reekie J. , Mocroft A. , Engsig F. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116: 5306–5315.

Baker J.V. , Peng G. , Rapkin J. CD4⁺ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22: 841–848.

Mocroft A. , Soriano V. , Rockstroh J. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19: 2117–2125.

HIV The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22: 2143–2153.

Moore R.D. , Gebo K.A. , Lucas G.M. , Keruly J.C. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 2008; 47: 1102–1104.

Smith C.J. , Olsen C.H. , Mocroft A. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS 2008; 22: 47–56.

The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632–1641.

Lichtenstein K.A. , Armon C. , Buchacz K. Low CD4⁺ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51: 435–447.

Phillips A.N. , Carr A. , Neuhaus J. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177–187.

Astor B.C. , Coresh J. , Heiss G. , Pettitt D. , Sarnak M.J. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006; 151: 492–500.

Schlichting P. , Christensen E. , Andersen P.K. Prognostic factors in cirrhosis identified by Cox's regression model. Hepatology 1983; 3: 889–895.

Cella D. , Kallich J. , McDermott A. , Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004; 15: 979–986.

Varat M.A. , Adolph R.J. , Fowler N.O. Cardiovascular effects of anemia. Am Heart J 1972; 83: 415–426.

Metivier F. , Marchais S.J. , Guerin A.P. , Pannier B. , London G.M. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000; 15 Suppl 3: 14–18.

Ludwig H. , Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25 Suppl 7: 2–6.

Belperio P.S. , Rhew D.C. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004; 116 Suppl 1: 27–43.

Henry D.H. , Volberding P.A. , Leitz G. Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future. J Acquir Immune Defic Syndr 2004; 37: 1221–1227.

Beutler E. , Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107: 1747–1750.